Skip to main content

A clinical audit of oral anticoagulant therapy in aged care residents with atrial fibrillation

International Journal of Clinical Pharmacy volume 42, pages 474–481 (2020)Cite this article

Abstract

Background Atrial fibrillation (AF) is a risk factor for stroke in older people. Oral anticoagulants can reduce stroke risk but they are commonly under prescribed in the elderly, often due to concerns regarding the risk of bleeding. Prescribing in aged care residents may also be further complicated by associated geriatric conditions such as dementia and risk of falls. Systematic assessment of stroke and bleed risk can help identify people with AF expected to benefit from anticoagulant therapy and optimise prescribing. Objective The aim of this study was to assess the prescribing of anticoagulants in elderly aged care residents in accordance with Australian guideline recommendations. Setting Nineteen aged care facilities across southeast Queensland. Method A clinical audit of anticoagulant therapy in aged care residents was conducted. Main outcome measure Information was collected from the records of residents with non-valvular AF to assess the risk of stroke and bleeding and compare this prescribing to current evidence-based guidelines for anticoagulation in AF. Results A total of 1754 residents were screened with 359 (20.4%) identified to have a diagnosis of non-valvular AF. There were 356 (99.2%) residents with non-valvular AF and a sufficiently high risk of stroke to warrant the use of an anticoagulant. Of these, 172 (48.3%) were prescribed an oral anticoagulant and 40 (11.2%) residents had a documented decision not to prescribe oral anticoagulants in their records. The majority of residents prescribed anticoagulation were receiving non-vitamin K antagonists (76.8%). The prescribed dose was consistent with recommendations for 44.8% of residents prescribed oral anticoagulant therapy. Conclusion Many residents with non-valvular AF and significant risk of stroke were not receiving oral anticoagulation despite a lack of documented reason for non-prescribing. Non-vitamin K antagonists were widely prescribed but dosing of these agents could still be improved. There remains a need to improve anticoagulant prescribing for aged care residents and optimise stroke prevention in this population.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest J. 2012;142(6):1489–98.

    Article  Google Scholar 

  2. Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol. 2013;167(6):2412–20.

    PubMed  Article  Google Scholar 

  3. RACGP. Guidelines for preventative activities in general practice. https://www.racgp.org.au/your-practice/guidelines/redbook/8-prevention-of-vascular-and-metabolic-disease/87-atrial-fibrillation/. Accessed 19 Dec 2019.

  4. Olsen TS, Rasmussen BH, Kammersgaard LP, Germer U. Strokes attributable to underuse of warfarin and antiplatelets. J Stroke Cerebrovasc Dis. 2005;14(2):55–7. https://doi.org/10.1016/j.jstrokecerebrovasdis.2004.11.003.

    PubMed  Article  Google Scholar 

  5. Rozzini R, Sleiman I, Trabucchi M. Warfarin prescribing in nursing homes. J Am Geriatr Soc. 2011;59(1):183–4.

    PubMed  Article  Google Scholar 

  6. Bahri O, Roca F, Lechani T, Druesne L, Jouanny P, Serot JM, et al. Underuse of oral anticoagulation for individuals with atrial fibrillation in a nursing home setting in France: comparisons of resident characteristics and physician attitude. J Am Geriatr Soc. 2015;63(1):71–6.

    PubMed  Article  Google Scholar 

  7. Nishtala P, Castelino R, Peterson G, Hannan P, Salahudeen M. Residential medication management reviews of antithrombotic therapy in aged care residents with atrial fibrillation: assessment of stroke and bleeding risk. J Clin Pharm Ther. 2016;41(3):279–84.

    CAS  PubMed  Article  Google Scholar 

  8. Virdee MS, Stewart D. Optimizing the use of oral anticoagulant therapy for atrial fibrilation in primary care: a pharmacist-led intervention. Int J Clin Pharm. 2017;39(1):173–80.

    PubMed  Article  Google Scholar 

  9. Brieger D, Amerena J, Attia J, Bajorek B, Chan KH, Connell C, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung Circ. 2018;27(10):1209–66. https://doi.org/10.1016/j.hlc.2018.06.1043.

    PubMed  Article  Google Scholar 

  10. Ziff OJ, Camm AJ. Individualized approaches to thromboprophylaxis in atrial fibrillation. Am Heart J. 2016;173:143–58.

    CAS  PubMed  Article  Google Scholar 

  11. Rossi S. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd; 2018.

    Google Scholar 

  12. Rosendaal F, Cannegieter S, Van der Meer F, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–9.

    CAS  PubMed  Article  Google Scholar 

  13. Rojas-Fernandez CH, Goh J, Hartwick J, Auber R, Zarrin A, Warkentin M, et al. Assessment of oral anticoagulant use in residents of long-term care homes: evidence for contemporary suboptimal use. Ann Pharmacother. 2017;51(12):1053–62.

    PubMed  Article  Google Scholar 

  14. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213–20.

    PubMed  PubMed Central  Article  Google Scholar 

  15. Wong CX, Brown A, Tse H-F, Albert CM, Kalman JM, Marwick TH, et al. Epidemiology of atrial fibrillation: the Australian and Asia-Pacific perspective. Heart Lung Circ. 2017;26(9):870–9.

    PubMed  Article  Google Scholar 

  16. Lefebvre M-CD, St-Onge M, Glazer-Cavanagh M, Bell L, Nguyen JNK, Nguyen PV-Q, et al. The effect of bleeding risk and frailty status on anticoagulation patterns in octogenarians with atrial fibrillation: the FRAIL-AF study. Can J Cardiol. 2016;32(2):169–76.

    PubMed  Article  Google Scholar 

  17. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–45.

    CAS  PubMed  Article  Google Scholar 

  18. Katz DF, Maddox TM, Turakhia M, Gehi A, Obrien EC, Lubitz SA, et al. Contemporary trends in oral anticoagulant prescription in atrial fibrillation patients at low to moderate risk of stroke after guideline- recommended change in use of the CHADS2 to the CHA2DS2-VASc score for thromboembolic risk assessment: analysis from the National Cardiovascular Data Registry’s Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry. Circulation. 2017;10(5):e003476.

    PubMed  Google Scholar 

  19. Patel AA, Nelson WW, Schein J. Impact of CHA2DS2VASc score on candidacy for anticoagulation in patients with atrial fibrillation: a multi-payer analysis. Clin Ther. 2016;38(10):2196–2203.e5.

    PubMed  Article  Google Scholar 

  20. Lane DA, Lip GY. Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 2012;126(7):860–5.

    PubMed  Article  Google Scholar 

  21. Obrien EC, Holmes DN, Ansell JE, Allen LA, Hylek E, Kowey PR, et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2014;167(4):601-9.e1.

    Google Scholar 

  22. Bo M, Brunetti E. Oral anticoagulant therapy for older patients with atrial fibrillation. Geriatric Care. 2017;3(3):18–27.

    Article  Google Scholar 

  23. Orkaby AR, Ozonoff A, Reisman JI, Miller DR, Zhao S, Rose AJ. Continued use of warfarin in veterans with atrial fibrillation after dementia diagnosis. J Am Geriatr Soc. 2017;65(2):249–56.

    PubMed  Article  Google Scholar 

  24. Moroney JT, Tseng CL, Paik MC, Mohr J, Desmond DW. Treatment for the secondary prevention of stroke in older patients: the influence of dementia status. J Am Geriatr Soc. 1999;47(7):824–9.

    CAS  PubMed  Article  Google Scholar 

  25. Donzé J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med. 2012;125(8):773–8.

    PubMed  Article  Google Scholar 

  26. Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118(6):612–7.

    PubMed  Article  Google Scholar 

  27. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159(7):677–85.

    CAS  PubMed  Article  Google Scholar 

  28. Culebras A, Messé SR, Chaturvedi S, Kase CS, Gronseth G. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(8):716–24.

    PubMed  PubMed Central  Article  Google Scholar 

  29. Lip GY, Banerjee A, Boriani G, en Chiang C, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–201.

    PubMed  Article  Google Scholar 

  30. Loo SY, Dell'Aniello S, Huiart L, Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83(9):2096–106.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation—quality and cost implications. Am J Med. 2014;127(11):1075–82.

    PubMed  Article  Google Scholar 

  32. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al. The changing landscape for stroke prevention in AF: findings from the GLORIA-AF Registry Phase 2. J Am Coll Cardiol. 2017;69(7):777–85.

    PubMed  Article  Google Scholar 

  33. Schwill S, Krug K, Peters-Klimm F, van Lieshout J, Laux G, Szecsenyi J, et al. Novel oral anticoagulants in primary care in patients with atrial fibrillation: a cross-sectional comparison before and after their introduction. BMC Fam Pract. 2018;19(1):115.

    PubMed  PubMed Central  Article  Google Scholar 

  34. Alamneh EA, Chalmers L, Bereznicki LR. The Tasmanian atrial fibrillation study: transition to direct oral anticoagulants 2011–2015. Cardiovasc Ther. 2017;35(3):e12254.

    Article  Google Scholar 

  35. Elewa H, El-Makaty H, Ali Z. Appropriateness of dabigatran and rivaroxaban prescribing in Qatar: a 5-year experience. J Cardiovasc Pharmacol Ther. 2018;23(2):155–61.

    CAS  PubMed  Article  Google Scholar 

  36. Whitworth MM, Haase KK, Fike DS, Bharadwaj RM, Young RB, MacLaughlin EJ. Utilization and prescribing patterns of direct oral anticoagulants. Int J Gener Med. 2017;10:87.

    CAS  Article  Google Scholar 

  37. Maffey M, Steel L, Gadowski T, Allard L, Tomlinson S. An audit of novel anticoagulant prescribing errors in non-valvular atrial fibrillation: an experience from a tertiary centre. Heart Lung Circ. 2018;27:S147.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the facilities, residents and prescribers who took part in the audit. We would also like to acknowledge the contribution of Sanam Souzani and staff at Aspect Health for their assistance and co-operation with this research.

Funding

Funding was received from the Collaborative Research Grant in Quality Use of Medicine and Pharmacy Practice from The University of Queensland School of Pharmacy and Griffith university School of Pharmacy & Pharmacology.

Conflicts of interest

The authors have no conflicts of interest to declare.

Author information

Affiliations

  1. School of Pharmacy and Pharmacology, Griffith University, Brisbane, Australia

    Nijole Bernaitis & Michelle Bowden

  2. Aspect Health, Brisbane, Australia

    Michelle Bowden

  3. School of Pharmacy, The University of Queensland, St Lucia, Australia

    Adam La Caze

Authors
  1. Nijole Bernaitis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle Bowden
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adam La Caze
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adam La Caze.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bernaitis, N., Bowden, M. & La Caze, A. A clinical audit of oral anticoagulant therapy in aged care residents with atrial fibrillation. Int J Clin Pharm 42, 474–481 (2020). https://doi.org/10.1007/s11096-020-01025-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-020-01025-0

Keywords

  • Aged care
  • Atrial fibrillation
  • Clinical audit
  • Oral anticoagulants
  • Pharmacy practice